Erytech Pharma S.A.

1.10-0.0600-5.17%Vol 9.23K1Y Perf -80.67%
Aug 5th, 2022 14:38 DELAYED
BID1.10 ASK1.15
Open1.16 Previous Close1.16
Pre-Market- After-Market-
 - -  - -%
Target Price
3.20 
Analyst Rating
Hold 3.00
Potential %
190.91 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.43 
Earnings Rating
Neutral
Market Cap34.12M 
Earnings Date
4th Apr 2022
Alpha-0.05 Standard Deviation0.23
Beta2.00 

Today's Price Range

1.101.16

52W Range

0.96006.72

5 Year PE Ratio Range

-6.10-2.70

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
3.77%
1 Month
2.80%
3 Months
-20.29%
6 Months
-41.80%
1 Year
-80.67%
3 Years
-81.45%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ERYP1.10-0.0600-5.17
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
Earnings HistoryEstimateReportedSurprise %
Q04 2019-0.86-1.21-40.70
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
3/2022 QR-0.670.00-
3/2022 QR-0.6772.20Positive
12/2022 FY-2.080.00-
12/2023 FY-1.970.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume9.23K
Shares Outstanding31.02K
Shares Float31.02M
Trades Count42
Dollar Volume10.29K
Avg. Volume15.74K
Avg. Weekly Volume11.46K
Avg. Monthly Volume10.34K
Avg. Quarterly Volume25.40K

Erytech Pharma S.A. (NASDAQ: ERYP) stock closed at 1.1 per share at the end of the most recent trading day (a -5.17% change compared to the prior day closing price) with a volume of 9.23K shares and market capitalization of 34.12M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 217 people. Erytech Pharma S.A. CEO is Gil Beyen.

The one-year performance of Erytech Pharma S.A. stock is -80.67%, while year-to-date (YTD) performance is -53.19%. ERYP stock has a five-year performance of %. Its 52-week range is between 0.96 and 6.72, which gives ERYP stock a 52-week price range ratio of 2.43%

Erytech Pharma S.A. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.41, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -73.11%, a ROC of -102.21% and a ROE of -217.87%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Erytech Pharma S.A., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Erytech Pharma S.A.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Erytech Pharma S.A. is Hold (3), with a target price of $3.2, which is +190.91% compared to the current price. The earnings rating for Erytech Pharma S.A. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Erytech Pharma S.A. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Erytech Pharma S.A. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.57, ATR14 : 0.10, CCI20 : 141.38, Chaikin Money Flow : 0.27, MACD : 0.00, Money Flow Index : 74.25, ROC : 1.85, RSI : 37.04, STOCH (14,3) : 50.00, STOCH RSI : 0.73, UO : 45.35, Williams %R : -50.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Erytech Pharma S.A. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Erytech Pharma S.A.

Erytech Pharma SA is a clinical-stage biopharmaceutical company. It is engaged in conducting activities in research and development in the fields of treatment for acute leukemia and other orphan diseases. The approach by the firm consists of acting on the tumor's environment and starving it so that the cancerous cells no longer have access to the growth factors that are necessary to live and proliferate. Most of the activities of the group are located in France. The company ERYCAPS proprietary platform to encapsulate active drug substances inside red blood cells using reversible hypotonic and hypertonic osmotic stress. The company's geographical segments are France and the United States, out of which the United States contributes to the majority of the revenue.

CEO: Gil Beyen

Telephone: +33 478744438

Address: 60 Avenue Rockefeller, Lyon 69008, , FR

Number of employees: 217

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

63%38%

Bearish Bullish

64%36%

Bearish Bullish

60%40%


News

Stocktwits